Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Results of a current study of women using the contraceptive injection depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City; Medroxyprogesterone Acetate Injectable Suspension USP, Teva Pharmaceuticals USA, North Wales, PA) indicate a modest increase in fracture risk compared with women using other contraceptive methods; however, the increased risk of fracture preceded the start of method use, analysis shows.

New research emerges on DMPA fracture risks